1.Sclerosing Stromal Tumor in an Elderly Postmenopausal Woman.
Tae Hee KIM ; Hae Hyeog LEE ; Jeong A HONG ; Junsik PARK ; Dong Su JEON ; Arum LEE ; Eun Suk KOH
Journal of Menopausal Medicine 2014;20(2):80-83
Sclerosing stromal tumor (SST) of the ovary is a rare tumor derived from the sex cord stroma. This tumor was first described by Chalvaridjian and Scully in 1973. SST of the ovary is prevalence of 1.5% to 6% of ovarian stromal tumors. Patients are most commonly diagnosed in their 20s and 30s. There have been reports of SST postmenopausal women aged 65-, 67-, and 71 in the Republic of Korea; however, no report of this disease has been reported in women older than 80. In this study, we would like to report an 80-year-old postmenopausal woman who did not previously complain of any symptoms, and was finally diagnosed with SST. She was involved in a traffic accident, and huge pelvic mass was found during the evaluation of intra-abdominal hemorrhage. Total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed ; a final pathologic diagnosis reported SST.
Accidents, Traffic
;
Aged*
;
Aged, 80 and over
;
Diagnosis
;
Female
;
Hemorrhage
;
Humans
;
Hysterectomy
;
Ovary
;
Postmenopause
;
Prevalence
;
Republic of Korea
;
Sex Cord-Gonadal Stromal Tumors
2.Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis.
Hyeon Gyu YI ; Moon Hee LEE ; Chul Soo KIM ; Junsik HONG ; Jinny PARK ; Jae Hoon LEE ; Bo Ram HAN ; Ho Young KIM ; Dae Young ZANG ; Se Hyung KIM ; Seong Kyu PARK ; Dae Sik HONG ; Guk Jin LEE ; Jong Youl JIN
Blood Research 2014;49(2):95-99
BACKGROUND: The clinical characteristics of elderly patients with AML differ from those of younger patients, resulting in poorer survival and treatment outcomes. We analyzed retrospectively the clinical data of AML patients 65 years old and above to describe patients' characteristics and treatment patterns, and to define meaningful prognostic factors of survival in the Korean population. METHODS: Basic patients' characteristics, clinical outcomes according to treatments, and prognostic factors associated with survival and treatment intensity were examined in a total of 168 patients diagnosed in 5 institutes between 1996 and 2012 as having AML. RESULTS: Herein, 84 patients (50.0%) received high-intensity regimens (HIR), 18 (10.7%) received low-intensity regimens (LIR), and 66 (39.3%) received supportive care (SC) only. The median survival of all patients was 4.5 months; and median survival times with HIR, LIR, and SC were 6.8 months, 10.2 months, and 1.6 months, respectively. Median survival times with HIR and LIR were significantly longer than that with SC (P<0.0001 and P=0.006, respectively). Multivariate analysis identified age, Eastern Cooperative Oncology Group-performance status (ECOG-PS), hemoglobin (Hb) level, and serum creatinine (Cr) level as statistically significant prognostic factors for survival. In the HIR group, prognostic factors for survival were ECOG-PS, Hb level, and C-reactive protein level. CONCLUSION: Even in elderly AML patients, an intensive treatment regimen could be beneficial with careful patient selection. Further prospective studies designed to identify specific prognostic factors are required to establish an optimal treatment strategy for elderly AML patients.
Academies and Institutes
;
Aged*
;
C-Reactive Protein
;
Creatinine
;
Drug Therapy
;
Humans
;
Korea
;
Leukemia, Myeloid, Acute*
;
Multivariate Analysis
;
Patient Selection
;
Prognosis
;
Retrospective Studies*
;
Treatment Outcome*
3.Hormone Therapy in Postmenopausal Women According to the Correlation of Changes in Bone Mineral Density.
Soo Ho CHUNG ; Tae Hee KIM ; Hae Hyeog LEE ; Junsik PARK ; Jae Hong SANG
The Journal of Korean Society of Menopause 2013;19(2):101-105
OBJECTIVES: We investigated the relationship between bone mineral density (BMD) and hormone therapy (HT) and its duration in postmenopausal women. METHODS: We performed a retrospective study on 291 postmenopausal women who had their BMD and follow-up BMD measured in a university hospital. We analyzed BMD, HT types and HT duration according to clinical characteristics. RESULTS: The mean age of the study subjects was 53.7 +/- 5.9 years. HT types and HT duration were not statistically related to improvement in BMD (P = 0.956, 0.483). But osteoporosis in patients with hormone therapy improves bone mineral density showed statistical significance (P = 0.001). CONCLUSION: HT types and HT duration did not have any effect on bone mineral density, but further prospective multicenter studies regarding HT should be considered for osteoporosis.
Bone Density
;
Female
;
Follow-Up Studies
;
Humans
;
Osteoporosis
;
Retrospective Studies

Result Analysis
Print
Save
E-mail